Scarica l'app Stockscreener
2.09
1.65%
-0.035
Dopo l'orario di chiusura:
2.09
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Casi Pharmaceuticals Inc Borsa (CASI) Ultime notizie
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated by Analysts at StockNews.com - Defense World
CASI Pharma stock hits 52-week low at $1.9 amid market challenges - Investing.com Australia
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely Bullish - MSN
CASI Pharmaceuticals receives buyout proposal from CEO By Investing.com - Investing.com South Africa
CASI Pharma stock hits 52-week low at $1.9 amid market challenges By Investing.com - Investing.com South Africa
CASI Pharmaceuticals Acquires Precision Autoimmune Therapeutics - TipRanks
Casi Pharmaceuticals Signs Agreement To Acquire Equity Interests In Precision Autoimmune Therapeutics - MarketScreener
CASI Pharma Stock Rises On $20M Buyout Offer From CEO For China Business Operations: Retail Remains Extremely - Asianet Newsable
CASI Pharmaceuticals receives buyout proposal from CEO - Investing.com India
CASI Pharmaceuticals Receives Updated Acquisition Proposal for China Operations - TipRanks
CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company - ACCESS Newswire
CASI Pharma's CEO Makes Strategic $20M Bid for Entire China BusinessKey Pipeline Assets Included - Stock Titan
CASI Pharmaceuticals Full Year 2024 Earnings: US$2.56 loss per share (vs US$2.02 loss in FY 2023) - Yahoo Finance
Short Interest in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Declines By 15.0% - Defense World
CASI Pharmaceuticals Reports 2024 Financial Results and Strategic Developments - TipRanks
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results - ACCESS Newswire
CASI Delivers Record Q4 Growth: FDA Clearance Powers Next-Gen Treatment Pipeline - Stock Titan
CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Shares Lagging The Industry But So Is The Business - Simply Wall St
CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by StockNews.com - Defense World
CASI Pharma stock hits 52-week low at $2.04 amid market challenges - Investing.com
StockNews.com Initiates Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
StockNews.com Begins Coverage on CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
CASI Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews.com - Defense World
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
CASI Pharmaceuticals (NASDAQ:CASI) Research Coverage Started at StockNews.com - Defense World
Multiple Myeloma Clinical and Non-Clinical Studies, Key - openPR
CASI Pharmaceuticals Secures Interim Relief in Juventas Dispute - TipRanks
Critical Comparison: Biora Therapeutics (NASDAQ:BIOR) versus CASI Pharmaceuticals (NASDAQ:CASI) - Defense World
Critical Contrast: Evolus (NASDAQ:EOLS) and Nuvectis Pharma (NASDAQ:NVCT) - Defense World
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
Multiple Myeloma Pipeline 2024: FDA Approvals, Therapies, - openPR
CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results - ACCESS Newswire
CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia - ACCESS Newswire
CASI Pharmaceuticals Faces Asset Freezing Amid Arbitration Dispute - TipRanks
Assenagon Asset Management S.A. Increases Stock Holdings in Premier, Inc. (NASDAQ:PINC) - Defense World
Can this 10.8% yield from a FTSE 250 share last? - Yahoo Finance UK
CASI Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia - Marketscreener.com
CASI Pharmaceuticals Launches Pivotal Phase 1/2 Trial for Novel ITP Treatment CID-103 - StockTitan
Major 2024 licensing deals confirm Asia’s ascent from copier to innovator - BioWorld Online
CASI Pharmaceuticals, Inc. Announces Clinical Hold of CID-103 for Antibody Mediated Rejection of Kidney Transplant - Marketscreener.com
CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA - TipRanks
CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE - The Eastern Progress Online
Is a stock market crash coming? And what should I do now? - Yahoo Finance UK
CASI Pharmaceuticals Faces Evomela® License Termination Dispute - TipRanks
Pre-market Movers: SXTC, STIM, BIOA, UPC... - RTTNews
Switch Therapeutics Appoints David M. Holtzman, M.D., to Its Scientific Advisory Board and Announces Its First Development Candidate, CASi-APOE, a Liver-Sparing APOE RNAi Therapy - BioSpace
The Market Doesn't Like What It Sees From CASI Pharmaceuticals, Inc.'s (NASDAQ:CASI) Revenues Yet As Shares Tumble 34% - Simply Wall St
CASI Pharmaceuticals Insider Ups Holding By 65% During Year - Simply Wall St
CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M - Marketscreener.com
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):